Guardian Pharmacy Services (NYSE:GRDN) Stock Rating Raised to Buy at Wall Street Zen

Wall Street Zen upgraded shares of Guardian Pharmacy Services (NYSE:GRDN) from a hold rating to a buy rating in a research note issued to investors on Saturday,Wall Street Zen reports.

Other analysts have also recently issued reports about the company. Oppenheimer raised their target price on Guardian Pharmacy Services from $43.00 to $49.00 and gave the stock an “outperform” rating in a research note on Friday, August 7th. KeyCorp began coverage on Guardian Pharmacy Services in a report on Tuesday, September 22nd. They set an “overweight” rating and a $52.00 price target on the stock. Truist Financial upped their price target on Guardian Pharmacy Services from $47.00 to $51.00 and gave the company a “buy” rating in a research report on Monday, September 21st. Finally, Weiss Ratings raised Guardian Pharmacy Services from a “buy (b-)” rating to a “buy (b)” rating in a research report on Thursday, October 8th. Nine investment analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to data from MarketBeat, Guardian Pharmacy Services currently has a consensus rating of “Moderate Buy” and a consensus target price of $45.57.

Guardian Pharmacy Services Stock Down 0.9%

Shares of GRDN opened at $39.34 on Friday. The stock has a market capitalization of $1.96 billion, a P/E ratio of 38.19, a PEG ratio of 2.06 and a beta of 0.03. The firm has a fifty day simple moving average of $40.83 and a two-hundred day simple moving average of $39.87. Guardian Pharmacy Services has a twelve month low of $23.72 and a twelve month high of $48.33.

Guardian Pharmacy Services (NYSE:GRDN) last announced its quarterly earnings results on Thursday, August 6th. The company reported $0.29 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.26 by $0.03. The business had revenue of $351.77 million for the quarter, compared to analyst estimates of $340.45 million. Guardian Pharmacy Services had a net margin of 4.50% and a return on equity of 29.97%. Sell-side analysts expect that Guardian Pharmacy Services will post 1.18 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. First Trust Advisors LP bought a new position in shares of Guardian Pharmacy Services in the 1st quarter worth approximately $3,528,000. Globeflex Capital L P purchased a new position in shares of Guardian Pharmacy Services in the 2nd quarter valued at approximately $1,857,000. Dimensional Fund Advisors LP boosted its position in shares of Guardian Pharmacy Services by 200.0% during the first quarter. Dimensional Fund Advisors LP now owns 208,594 shares of the company’s stock valued at $7,855,000 after purchasing an additional 139,070 shares in the last quarter. Bank of America Corp DE boosted its position in shares of Guardian Pharmacy Services by 86.1% during the first quarter. Bank of America Corp DE now owns 128,048 shares of the company’s stock valued at $4,822,000 after purchasing an additional 59,245 shares in the last quarter. Finally, Sanctuary Advisors LLC bought a new stake in shares of Guardian Pharmacy Services during the first quarter valued at approximately $1,352,000.

Guardian Pharmacy Services Company Profile

Guardian Pharmacy Services, Inc (NYSE: GRDN) is a healthcare services company that provides pharmacy services to residents of long-term care and other institutional healthcare settings. Its customers include assisted living communities, skilled nursing facilities, behavioral health centers and communities serving individuals with developmental disabilities.

The company’s services include prescription dispensing, medication packaging and delivery, medication management, pharmacy consulting and clinical support.